RAS interaction with PI3K p110α is required for tumor-induced angiogenesis

Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance

(2013) Esther Castellano et al.   CANCER CELL

Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis

(2013) Adriana Soler et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Modulation of macrophage phenotype by cell shape

(2013) F. Y. McWhorter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

(2012) R. C. Doebele et al.   ANNALS OF ONCOLOGY

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

(2012) M. Mao et al.   CLINICAL CANCER RESEARCH

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

(2012) P. J. Roberts et al.   CLINICAL CANCER RESEARCH

Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

(2012) R. S. Finn et al.   CLINICAL CANCER RESEARCH

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

(2012) Giorgio V. Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401

(2012) William Kevin Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Neuropilin 1 deficiency on CD4+Foxp3+regulatory T cells impairs mouse melanoma growth

(2012) Wiebke Hansen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Antiangiogenic therapy—evolving view based on clinical trial results

(2012) Gordon C. Jayson et al.   Nature Reviews Clinical Oncology

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

(2012) Harry D. Bear et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis

(2012) R. Cao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

(2011) J. Cortes et al.   ANNALS OF ONCOLOGY

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer

(2011) Seong Yong Park et al.   ANNALS OF THORACIC SURGERY

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

(2011) C. Lieu et al.   CLINICAL CANCER RESEARCH

Treatment-Related Mortality With Bevacizumab in Cancer Patients

(2011) Vishal Ranpura et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting stroma to treat cancers

(2011) Boris Engels et al.   SEMINARS IN CANCER BIOLOGY

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions

(2009) Irma Airoldi et al.   PLoS One

Immune Therapy for Cancer

(2008) Michael Dougan et al.   Annual Review of Immunology

Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

(2008) Mariona Graupera et al.   NATURE

K-ras/PI3K-Akt Signaling Is Essential for Zebrafish Hematopoiesis and Angiogenesis

(2008) Lihui Liu et al.   PLoS One

Co-evolution of tumor cells and their microenvironment

(2008) Kornelia Polyak et al.   TRENDS IN GENETICS